Viewing Study NCT02957292


Ignite Creation Date: 2025-12-24 @ 3:56 PM
Ignite Modification Date: 2026-01-03 @ 7:13 PM
Study NCT ID: NCT02957292
Status: COMPLETED
Last Update Posted: 2021-10-28
First Post: 2016-11-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D016912', 'term': 'Levonorgestrel'}, {'id': 'D007434', 'term': 'Intrauterine Devices'}], 'ancestors': [{'id': 'D009644', 'term': 'Norgestrel'}, {'id': 'D009652', 'term': 'Norpregnenes'}, {'id': 'D009650', 'term': 'Norpregnanes'}, {'id': 'D009654', 'term': 'Norsteroids'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D003274', 'term': 'Contraceptive Devices, Female'}, {'id': 'D003273', 'term': 'Contraceptive Devices'}, {'id': 'D004864', 'term': 'Equipment and Supplies'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 108}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-06-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-10', 'completionDateStruct': {'date': '2020-09-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-10-22', 'studyFirstSubmitDate': '2016-11-04', 'studyFirstSubmitQcDate': '2016-11-04', 'lastUpdatePostDateStruct': {'date': '2021-10-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-11-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-09-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of menstrual bleeding days', 'timeFrame': '90 days', 'description': 'Daily recorded during 90 days treatment period'}, {'measure': 'Amount of Menstrual bleeding', 'timeFrame': '90 days', 'description': 'Classified using a 5-item Likert-like scale from none to heavy, a pictorial blood loss assessment chart (PBAC), and ferritin and haemoglobin blood test determinations'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Contraception']}, 'descriptionModule': {'briefSummary': 'The intrauterine device (IUD) is a long-term birth control method that has demonstrated high contraceptive efficacy and effectiveness due to its high compliance, adherence and persistence of use. The IUD has a global prevalence rate around 14% in women of reproductive age.\n\nSide effects are the main reason for IUD use discontinuation. The most common reasons for copper IUD discontinuation are increased menstrual bleeding, irregular bleeding and dysmenorrhea, whereas in the case of 52mg Levonorgestrel IUD are irregular bleeding and amenorrhea.\n\nIn 2014, a new hormonal IUD containing13,5mg of Levonorgestrel was marketed in Spain. There are many studies comparing the two Levonorgestrel IUDs. However, there is any study comparing the IUD 13,5mg Levonorgestrel with classic copper IUDs.\n\nThe hypothesis of this trial is that Levonorgestrel (13,5mg) IUD users have a menstrual bleeding pattern with fewer days than Copper 380 mm2 IUD users.\n\nThis is a Phase IV, national single-center, randomized 1: 1, single-blind, comparative, parallel controled trial.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Healthy female subject.\n* Parous or nulliparous women aged between 18 and 45 years who ask for an IUD as a contraceptive method.\n* History of regular cyclic menstrual periods ranged from 21 to 35 days with non-excessive menstrual blood loss.\n\nExclusion Criteria:\n\n* Absolute contraindications to IUD use, according to the World Health Organization Medical Eligibility Criteria.\n* Contraindications to use 13,5 LNG-IUD.\n* Anemia.\n* Use of short or long-acting preparations containing sex hormones within the 12 weeks before the IUD insertion.\n* Known bleeding irregularities.\n* Pregnancy or breast-feeding.'}, 'identificationModule': {'nctId': 'NCT02957292', 'acronym': 'COLIBRI', 'briefTitle': 'A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).', 'organization': {'class': 'OTHER', 'fullName': "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"}, 'officialTitle': 'A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users.', 'orgStudyIdInfo': {'id': 'IIBSP-DIU-2015-85'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Levonorgestrel IUD', 'description': '13,5 mg Levonorgestrel intrauterine device', 'interventionNames': ['Drug: Levonorgestrel (13,5 mg) intrauterine device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Copper IUD', 'description': 'Copper (380mm2) intrauterine device', 'interventionNames': ['Device: Cooper (380mm2) intrauterine device']}], 'interventions': [{'name': 'Levonorgestrel (13,5 mg) intrauterine device', 'type': 'DRUG', 'armGroupLabels': ['Levonorgestrel IUD']}, {'name': 'Cooper (380mm2) intrauterine device', 'type': 'DEVICE', 'armGroupLabels': ['Copper IUD']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08025', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital de la Santa Creu i Sant Pau', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 'class': 'OTHER'}, 'collaborators': [{'name': 'Bayer', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}